zur Navigation zum Inhalt
 
Onkologie 25. März 2016

Treatment of elderly and very old patients with AML

Acute Myeloid Leukemia (AML) is a genetically heterogeneous malignant disease mainly occurring in elderly patients. The prognosis of patients over 60 years of age, which represent the majority of patients, which are diagnosed, remains poor. The main reasons for the poor outcome are the in-creasing number of comorbidities, organ impairments and nevertheless the unfavorable genetic features, pre-existing myelodysplastic changes and rising multi-drug resistance. It is also more likely that older and frail patients are not included into clinical trials and treatment decisions have to be made on general assumptions.

Introduction

Acute myeloid leukemia (AML) is a genetically heterogeneous malignant disease mainly occurring in the elderly population. The prognosis of patients more than 60 years of age, which represent the majority of all patients diagnosed, remains poor. The main reasons for the poor outcome are the increasing number of comorbidities, organ impairments and, nevertheless, the unfavorable genetic features, pre-existing myelodysplastic changes, and the increase of multidrug resistance. It is also more likely that older and frail patients are not included into clinical trials, and treatment decisions have to be made on general assumptions.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben